CVA Family Office LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

CVA Family Office LLC trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 140 shares of the biopharmaceutical company’s stock after selling 25 shares during the period. CVA Family Office LLC’s holdings in Regeneron Pharmaceuticals were worth $74,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Creative Financial Designs Inc. ADV grew its position in shares of Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 19 shares in the last quarter. Private Trust Co. NA grew its holdings in Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 19 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 6.2% during the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 19 shares during the period. Cove Private Wealth LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 20 shares in the last quarter. Finally, Marino Stram & Associates LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 20 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on REGN shares. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a report on Friday, August 1st. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Sanford C. Bernstein boosted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $802.35.

Regeneron Pharmaceuticals Trading Up 0.4%

NASDAQ REGN opened at $577.95 on Monday. The stock’s 50-day simple moving average is $576.32 and its two-hundred day simple moving average is $562.53. The company has a market capitalization of $61.26 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $943.83. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the business posted $11.56 EPS. The business’s quarterly revenue was up 3.6% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.